Clinical Trials on Recurrent Primary Peritoneal Cancer in Korea, Democratic People's Republic of

Total 510 results

BicycleTx Limited

Recruiting

Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression

Head and Neck Cancer | Ovarian Cancer | Triple Negative Breast Cancer | Non-small Cell Lung Cancer | Advanced Solid Tumor Historically Known for High EphA2 Expression | Urothelial Cancer | Gastric/Upper Gastrointestinal Cancer

United States, Belgium, Korea, Republic of, Spain, United Kingdom
Galena Biopharma, Inc.

Completed

Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence (PRESENT)

Breast Cancer With Low to Intermediate HER2 Expression

United States, United Kingdom, France, Israel, Germany, Canada, Russian Federation, Romania, Bulgaria, Czech Republic, Hungary, Poland, Ukraine
Novartis Pharmaceuticals

Completed

A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer

Endometrial Cancer | VEGF | Solid Tumors and Advanced Endometrial Cancer | Second-line Treatment

Italy, United Kingdom, Spain, Brazil, United States, Korea, Republic of, New Zealand
ppharmaand GmbH
Bristol-Myers Squibb; Gynecologic Oncology Group; European Network of Gynaecological... and other collaborators

Active, not recruiting

A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy (ATHENA)

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Primary Peritoneal | Newly Diagnosed | FIGO Stage III-IV | Partial Response | Complete Response

United States, United Kingdom, Korea, Republic of, Russian Federation, Canada, Denmark, Taiwan, New Zealand, Ireland, Japan, Spain, Australia, Israel, Italy, Greece, Sweden, Czechia, Finland, Poland, Belgium, Germany, Romania, Singa... and more
Taiho Oncology, Inc.

Completed

A Study of TAS-120 in Patients With Advanced Solid Tumors

Breast Cancer | Gastric Cancer | Cholangiocarcinoma | Urothelial Cancer | Primary CNS Tumors | Advanced and Metastatic Cancer Patients With Tumors Harboring FGF/FGFR Tumors

France, United States, Korea, Republic of, United Kingdom, Japan, Hong Kong, Australia, Taiwan, Italy, Canada, Germany, Netherlands, Spain
Day One Biopharmaceuticals, Inc.

Recruiting

Tovorafenib (DAY101) Monotherapy or in Combination With Other Therapies for Patients With Melanoma and Other Solid Tumors

Melanoma | Colorectal Cancer | Solid Tumor | Non Small Cell Lung Cancer | Bladder Cancer | Thyroid Cancer, Papillary | Pilocytic Astrocytoma | Bladder Urothelial Carcinoma | Non-Small Cell Adenocarcinoma | MEK Mutation | RAS Mutation | Pancreatic Acinar Carcinoma | RAF Mutation | CRAF Gene Amplification | RAF1 Gene Amplification and other conditions

United States, Canada, Korea, Republic of, Spain, Australia, Belgium, France
Elevation Oncology

Active, not recruiting

Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors

Sarcoma | Kidney Cancer | Breast Cancer | Head and Neck Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Lung Cancer | Prostate Cancer | Cholangiocarcinoma | Bile Duct Cancer | Bladder Cancer | Metastatic Solid Tumor | Gallbladder Cancer | Uterine Cancer | Locally Advanced Solid Tumor

United States, Korea, Republic of, Australia, Canada
Protara Therapeutics

Recruiting

Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer (Phase 1a) (ADVANCED-1)

Non-muscle Invasive Bladder Cancer

United States, Moldova, Republic of, Romania, Ukraine
Byondis B.V.

Completed

SYD985 in Patients With HER2-expressing Recurrent, Advanced or Metastatic Endometrial Carcinoma

Endometrial Cancer

Korea, Republic of, Singapore, Russian Federation, Ukraine, United States, Poland, Serbia
RAPT Therapeutics, Inc.
Merck Sharp & Dohme LLC

Active, not recruiting

Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab

Advanced Cancer

Hong Kong, United States, Australia, Korea, Republic of, Taiwan, Thailand
Eli Lilly and Company

Active, not recruiting

A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer (EMBER)

Breast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Endometrial Cancer

United States, Spain, France, Belgium, Taiwan, Australia, Korea, Republic of, Japan
Ascendis Pharma Oncology Division A/S

Recruiting

A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or Chemotherapy or TransCon TLR7/8 Agonist in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies (IL Believe)

Advanced Solid Tumor | Metastatic Solid Tumor | Platinum-resistant Ovarian Cancer | Locally Advanced Solid Tumor | Post Anti-PD-1 Melanoma | 2L+ Cervical Cancer | Neoadjuvant Melanoma | Neoadjuvant Non-Small Cell Lung Cancer | Post Anti-PD-(L)1 Non-Small Cell Lung Cancer | Post Anti-PD-(L)1 Small Cell...

United States, Korea, Republic of, Poland, Australia, Belgium, Canada, Italy, Singapore, Spain, Taiwan
Coherus Biosciences, Inc.
Merck Sharp & Dohme LLC

Recruiting

Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors

Clear Cell Renal Cell Carcinoma | Hepatocellular Carcinoma | Advanced Solid Tumor | Non-small Cell Lung Cancer

Korea, Republic of, United States, Singapore
Regeneron Pharmaceuticals
Sanofi

Completed

Study of Cemiplimab in Adults With Cervical Cancer

Squamous Cell Carcinoma (SCC) | Recurrent or Metastatic, Platinum-refractory Cervical Cancer

Spain, Korea, Republic of, United States, United Kingdom, Taiwan, Brazil, Belgium, Australia, Italy, Canada, Japan, Greece, Poland, Russian Federation
Hoffmann-La Roche
Gilead Sciences, Inc., GlaxoSmithKline plc, Seattle Genetics and Astellas

Recruiting

Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)

Bladder Cancer | Urothelial Carcinoma

United States, Spain, Korea, Republic of, United Kingdom, Taiwan, France, Greece
Mirati Therapeutics Inc.

Completed

Phase 1/1b Study of MGCD516 in Patients With Advanced Cancer

Advanced Cancer

Korea, Republic of, United States
Merck Sharp & Dohme LLC

Recruiting

Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)

Cervical Cancer | Small Cell Lung Carcinoma | Neuroendocrine Tumor | Advanced Solid Tumors | Mesothelioma | Vulvar Cancer | Cholangiocarcinoma | Bile Duct Cancer | Endometrial Cancer | Advanced Cancer | Cervical Carcinoma | Endometrial Carcinoma | Thyroid Carcinoma | Thyroid Cancer | Anal Cancer | Colorectal Carcinoma | Carcinoid... and other conditions

Canada, France, Germany, Italy, Mexico, Netherlands, Poland, Russian Federation, Taiwan, United States, Brazil, Colombia, Israel, Korea, Republic of, Norway, Philippines, South Africa, Spain, Australia, Denmark, Chile, Portugal, Peru
AstraZeneca
Myriad Genetic Laboratories, Inc.

Withdrawn

Olaparib Maintenance Treatment Versus Placebo in Patients With PSR Ovarian Cancer Who Are in CR or PR to Platinum-based Chemotherapy and Whose Tumours Carry sBRCAm or HRR-associated Genes Mutations

Platinum Sensitive Relapsed Ovarian Cancer

United States, Korea, Republic of, Peru, United Kingdom, Philippines
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Completed

Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300)

Unresectable, Recurrent, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma | Gastric Cancer Third Line

Spain, Italy, Australia, Korea, Republic of, Belgium, France, Poland, United States, Czechia, Germany
AstraZeneca
Iqvia Pty Ltd

Active, not recruiting

A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors. (MEDIOLA)

SCLC | Breast | Ovarian | Gastric Cancers

United Kingdom, United States, Korea, Republic of, France, Netherlands, Israel, Switzerland
AstraZeneca

Recruiting

Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents

Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer

Spain, United States, Belgium, United Kingdom, France, Hungary, Canada, Korea, Republic of, Australia
Hoffmann-La Roche
Foundation Medicine, Inc.

Active, not recruiting

A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site (CUPISCO)

Cancer of Unknown Primary Site

United Kingdom, Korea, Republic of, France, Australia, Germany, Austria, Croatia, Denmark, Finland, Greece, Hungary, Italy, Portugal, Spain, Japan, Brazil, Colombia, Mexico, Romania, Czechia, Norway, Thailand, Switzerland, Turkey, Nethe... and more
Pfizer

Recruiting

Study of PF-07248144 in Advanced or Metastatic Solid Tumors (KAT6)

Locally Advanced or Metastatic ER+ HER2- Breast Cancer | Locally Advanced or Metastatic Castration-resistant Prostate Cancer | Locally Advanced or Metastatic Non-small Cell Lung Cancer

United States, China, Australia, Korea, Republic of, Japan
Novartis Pharmaceuticals

Active, not recruiting

Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers

Renal Cell Carcinoma | Colorectal Cancer | Gastroesophageal Cancer

United Kingdom, Australia, Belgium, Germany, Italy, Taiwan, Czechia, Israel, Spain, Japan, Singapore, Canada, Korea, Republic of, United States, Chile
Philipps University Marburg Medical Center
German Research Foundation

Completed

Lymphadenectomy In Ovarian Neoplasms (LION)

Ovarian Cancer

Germany, Italy, Austria, Belgium, Czechia, Korea, Republic of
Merck Sharp & Dohme LLC
Eisai Inc.

Active, not recruiting

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)

Glioblastoma | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | Advanced Solid Tumors | Triple Negative Breast Cancer | Biliary Tract Cancers

United States, Argentina, Australia, Canada, Chile, Colombia, France, Germany, Israel, Italy, Korea, Republic of, Russian Federation, Spain, Switzerland, Taiwan, Thailand, United Kingdom
AstraZeneca

Recruiting

Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies (PETRA)

Cervical Cancer | Breast Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | Prostate Cancer | Bladder Cancer | Endometrial Cancer | Non-small Cell Lung Cancer | Biliary Cancer | Additional Indications Below for Module 4 and 5 | Small Cell Lung Cancer Only in Module 5

Canada, China, Spain, Korea, Republic of, Italy, Poland, United States, Australia, United Kingdom, Japan, Hungary, Russian Federation, Czechia
Hoffmann-La Roche

Terminated

A Study of Taselisib + Fulvestrant Versus Placebo + Fulvestrant in Participants With Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase Inhibitor Therapy (SANDPIPER)

Breast Cancer

Italy, United States, Korea, Republic of, Canada, Czechia, Spain, Australia, Bulgaria, China, Finland, France, Greece, Poland, Portugal, Taiwan, Thailand, Turkey, Colombia, Bosnia and Herzegovina, Mexico, Peru, Romania, Russian Federation and more
Queensland Centre for Gynaecological Cancer
M.D. Anderson Cancer Center

Completed

Laparoscopic Approach to Cervical Cancer (LACC)

Cervical Cancer

United States, China, Korea, Republic of, Australia, Canada, Italy, Argentina, Brazil, Bulgaria, Colombia, Mexico, Peru, Puerto Rico
Novartis Pharmaceuticals

Completed

Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies

Melanoma | Triple Negative Breast Cancer | Endometrial Carcinoma | Pancreatic Carcinoma

United States, Germany, Italy, Japan, Belgium, Switzerland, Korea, Republic of, Hong Kong, Finland, France, Spain
Astellas Pharma Global Development, Inc.

Completed

A Study to Describe Patterns of Care and Outcomes of Men Who Are at High Risk After Experiencing Biochemical Failure Following Definitive Prostate Cancer Therapy, Men With Castration-resistant Prostate Cancer and Men With Metastatic Prostate Cancer (ASPIRE-PCa)

Prostate Cancer | Castration-resistant Prostate Cancer | Metastatic Prostate Cancer

Spain, Taiwan, France, Algeria, Argentina, Australia, Austria, Brazil, Canada, Colombia, Egypt, Germany, Indonesia, Israel, Italy, Korea, Republic of, Lebanon, Mexico, Netherlands, New Zealand, Oman, Peru, Philippines, Saudi Arabia, Sin... and more
National Cancer Institute (NCI)
NRG Oncology

Completed

Fludeoxyglucose (FDG) F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer

Cervical Adenocarcinoma | Cervical Squamous Cell Carcinoma | Cervical Small Cell Carcinoma | Stage IB Cervical Cancer | Stage IIA Cervical Cancer | Stage IIB Cervical Cancer | Stage III Cervical Cancer | Stage IVA Cervical Cancer | Endometrial Clear Cell Carcinoma | Stage III Endometrial Carcinoma | Cervical... and other conditions

United States, Korea, Republic of, Japan, Canada
PMV Pharmaceuticals, Inc
Merck Sharp & Dohme LLC

Recruiting

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

Breast Cancer | Head and Neck Cancer | Colorectal Cancer | Ovarian Cancer | Lung Cancer | Prostate Cancer | Metastatic Cancer | Advanced Solid Tumor | Endometrial Cancer | Metastatic Solid Tumor | Other Cancer | Advanced Malignant Neoplasm | Locally Advanced

United States, Spain, Korea, Republic of, Singapore, Australia, France, Germany, Italy, United Kingdom
Pfizer

Active, not recruiting

Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing

Ovarian Cancer | NSCLC | Solid Tumors | Urothelial Cancer | Advanced Malignancies

Hungary, Spain, United States, Canada, Taiwan, Japan, Serbia, Italy, New Zealand, Australia, Mexico, Russian Federation, United Kingdom, France, Korea, Republic of, Belgium, Poland, Denmark, Israel
AstraZeneca

Recruiting

A Phase I/IIa Study of AZD8205 Given Alone or in Combination With Anticancer Drugs, in Participants With Advanced or Metastatic Solid Malignancies

Breast Cancer | Ovarian Cancer | Endometrial Cancer | Biliary Tract Carcinoma

United States, Australia, Spain, United Kingdom, Korea, Republic of, Canada, Italy, Poland, Belgium, China, Japan, Taiwan, Thailand, Hungary, Netherlands
Revolution Medicines, Inc.

Active, not recruiting

Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors

Advanced Solid Tumor | Pancreatic Ductal Adenocarcinoma | Non-Small Cell Lung Cancer (NSCLC) | Colorectal Cancer (CRC)

United States, Spain, France, Korea, Republic of, Malaysia, Taiwan, Italy, Thailand, Australia, Czechia, Singapore, Poland, Serbia
Regeneron Pharmaceuticals
ISA Pharmaceuticals B.V.

Active, not recruiting

Cemiplimab and ISA101b Vaccine in Adult Participants With Recurrent/Metastatic Human Papillomavirus (HPV)16 Cervical Cancer Who Have Experienced Disease Progression After First Line Chemotherapy

Cervical Cancer

Spain, Korea, Republic of, Netherlands, Brazil, Belgium, United States, Italy, Russian Federation
AstraZeneca
Daiichi Sankyo

Recruiting

Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

Gastric Cancer | Colorectal Cancer | Ovarian Cancer | Endometrial Cancer | Urothelial Cancer | Biliary Tract Cancer | Metastatic Castration-resistant Prostate Cancer

Spain, China, Korea, Republic of, Canada, Italy, Poland, Turkey, United Kingdom, Japan, Taiwan, United States, France, Germany, Switzerland
Hoffmann-La Roche

Recruiting

A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy (Astefania)

Breast Cancer

Korea, Republic of, United States, Australia, China, Ukraine, Spain, United Kingdom, Turkey, Mexico, Brazil, Belgium, Denmark, Germany, Greece, Portugal, Russian Federation, Taiwan, France, Kenya, Thailand, Romania, Italy, Czechia, Hu... and more
AstraZeneca

Active, not recruiting

Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer (NILE)

Metastatic Urothelial Cancer | Unresectable Locally Advanced Urothelial Cancer

United States, Italy, Spain, Canada, Hungary, Poland, Argentina, Thailand, Vietnam, Turkey, Korea, Republic of, Brazil, Czechia, India, Japan, Philippines, Russian Federation, China, Taiwan, Israel, Australia, Bulgaria
AstraZeneca

Enrolling by invitation

Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib (ROSY-O)

Breast Cancer | Ovarian Cancer

Italy, Spain, United States, Canada, Belgium, Denmark, Korea, Republic of, Czechia, Turkey, China, United Kingdom, Taiwan, Brazil, Israel, France, Hungary, Poland, Portugal, Germany, Russian Federation, Bulgaria, Finland, Slovenia, Sw...
Eli Lilly and Company

Completed

A Study of Prexasertib (LY2606368) in Platinum-Resistant or Refractory Recurrent Ovarian Cancer

Ovarian Cancer

United States, Israel, Spain, Korea, Republic of, Australia, Belgium, United Kingdom, Italy
Pfizer

Completed

A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.

Hepatocellular Carcinoma | Advanced Breast Cancer | Non-Small Cell Lung Cancer | Metastatic Breast Cancer | Metastatic Renal Cell Cancer | Thyroid Cancer | Pancreatic Neuroendocrine Tumor | Gastrointestinal Stromal Tumor | Advanced Gastric Cancer | Metastatic Castration Resistant Prostate Cancer | Advanced... and other conditions

United States, Spain, Korea, Republic of, France, Australia, United Kingdom, Canada, Brazil, Argentina, Taiwan, Belgium, Colombia, Germany, Hong Kong, Mexico, Philippines, Singapore
AbbVie

Recruiting

Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors

Advanced Solid Tumors Cancer

United States, Australia, Israel, Japan, Korea, Republic of, Puerto Rico, Spain, Taiwan, Canada, France, Belgium
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Korea, Republic of, United States, Spain, France, Belgium, China, Taiwan, United Kingdom, Australia, Czechia, Hungary, Poland, Russian Federation
Advaxis, Inc.
Gynecologic Oncology Group

Terminated

Study of ADXS11-001 in Participants With High Risk Locally Advanced Cervical Cancer (AIM2CERV)

High Risk Cervical Cancer | Advanced Cervical Cancer

United States, Argentina, Brazil, Canada, Chile, Korea, Republic of, Malaysia, Mexico, Poland, Russian Federation, Serbia, Spain, Taiwan, Ukraine
Amgen

Recruiting

Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer

Prostate Cancer

Japan, United States, Korea, Republic of, Taiwan, Australia, Spain, Germany, Switzerland, China, Portugal
Schrödinger, Inc.

Recruiting

Study of SGR-1505 in Mature B-Cell Neoplasms

Follicular Lymphoma | Splenic Marginal Zone Lymphoma | Burkitt Lymphoma | Plasmablastic Lymphoma | Waldenstrom Macroglobulinemia | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Lymphoplasmacytic Lymphoma | Non Hodgkin Lymphoma | Primary Effusion Lymphoma | DLBCL | High-grade B-cell Lymphoma | Primary Mediastinal... and other conditions

United States, Moldova, Republic of
Exelixis

Recruiting

Study of XB002 in Subjects With Solid Tumors (JEWEL-101)

Cervical Cancer | Pancreatic Cancer | Non Small Cell Lung Cancer | Triple Negative Breast Cancer | Endometrial Cancer | Epithelial Ovarian Cancer | Metastatic Castration-resistant Prostate Cancer | Hormone Receptor-positive Breast Cancer | SCCHN | Esophageal SCC | Tissue Factor-Expressing Solid Tumors

United States, Spain, Australia, Belgium, France, Italy, Netherlands, United Kingdom, Korea, Republic of
Pfizer

Terminated

Avelumab and Talazoparib in Untreated Advanced Ovarian Cancer (JAVELIN OVARIAN PARP 100)

Ovarian Cancer

Korea, Republic of, United States, Singapore, Taiwan, Japan, Italy, Australia, Belgium, Ireland, Russian Federation

Clinical Trials on Recurrent Primary Peritoneal Cancer in Korea, Democratic People's Republic of

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Congo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations